Daniel Stetson

Company: AstraZeneca

Job title: Director- Translational Genomics

Seminars:

Incorporating MRD Detection & Cell-Free DNA into Clinical Trials: A Comprehensive Overview 12:45 pm

Advanced patient selection strategies in clinical trials: Leveraging cell-free DNA (cfDNA) for precise patient stratification and selection to enhance trial outcomes and personalized medicine Innovative detection of minimal residual disease (MRD) and patient surveillance: Utilizing cfDNA as a cutting-edge tool for monitoring MRD and conducting ongoing patient surveillance, improving early detection and intervention Technological innovation:…Read more

day: Day Two